Home>>Signaling Pathways>> Ubiquitination/ Proteasome>> Autophagy>>Sunitinib

Sunitinib Sale

(Synonyms: 舒尼替尼; SU 11248) 目录号 : GC17651

舒尼替尼Sunitinib(SU 11248)是一种具口服活性的多靶点受体酪氨酸激酶抑制剂,对血管内皮生长因子受体(VEGFR2)和血小板衍生生长因子受体(PDGFRβ)的IC50分别为80nM和2nM。

Sunitinib Chemical Structure

Cas No.:557795-19-4

规格 价格 库存 购买数量
10mM (in 1mL DMSO)
¥410.00
现货
100mg
¥368.00
现货
500mg
¥725.00
现货
1g
¥1,155.00
现货
2g
¥1,575.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

实验参考方法

Cell experiment [1]:

Cell lines

786-O cells

Preparation Method

Phosphoproteome analysis was performed on lysates of 786-O cells that were untreated or exposed to 2 and 5 μM sunitinib for 2 h. Treatment with 1.0 μM staurosporine was used as a positive control for inhibition of tyrosine kinases.

Reaction Conditions

2、5μM; 2h

Applications

At both sunitinib concentrations, 180 phosphopeptides from 129 proteins showed >1.5-fold changes in more than 2 out of 3 experiments. Of these, 86 phosphopeptides were downregulated and 94 were upregulated.
Animal experiment [2]:

Animal models

Female Balb/c mice

Preparation Method

Female Balb/c mice were injected intravenously with 4T1-luc or RENCA-luc tumor cells. Drugs (30, 60, or 120 mg/kg/day sunitinib) were given by oral gavage for 7 days.

Dosage form

30, 60, 120 mg/kg/day; p.o.

Applications

Sunitinib fails to inhibit the growth of 4T1 tumours after they have seeded in the lungs of mice, sunitinib can significantly suppress the growth of RENCA tumours.

References:

[1] Van Der Mijn J C, Broxterman H J, Knol J C, et al. Sunitinib activates Axl signaling in renal cell cancer[J]. International journal of cancer, 2016, 138(12): 3002-3010.

[2] Welti J C, Powles T, Foo S, et al. Contrasting effects of sunitinib within in vivo models of metastasis[J]. Angiogenesis, 2012, 15: 623-641.

产品描述

Sunitinib (SU 11248) is an orally active multi-target receptor tyrosine kinase inhibitor with IC50 values of 80 nM and 2 nM for vascular endothelial growth factor receptor (VEGFR2) and platelet-derived growth factor receptor (PDGFRβ), respectively[1]. Sunitinib is an ATP-competitive inhibitor that effectively inhibits the phosphorylation of Ire1α by inhibiting autophosphorylation and subsequent RNase activation[2]. Sunitinib is commonly used to treat advanced renal cell carcinoma and gastrointestinal stromal cancer, as well as non-small cell lung cancer[3].

In vitro, treatment of renal cancer cell 786-O with Sunitinib (2, 5 μM) induced changes in the intracellular phosphorylated proteome, with 180 phosphopeptides showing >1.5-fold changes, 86 phosphopeptides downregulated, and 94 phosphopeptides upregulated[4]. Sunitinib (0-5μM) treatment of medulloblastoma VC312 cells for 24h or 48h increased the levels of cleaved caspase-3 and PARP in a dose-dependent manner, induced cell apoptosis, and inhibited STAT3 and AKT activity[5].

In vivo, oral treatment of mice inoculated with 4T1-luc and RENCA-luc tumor cells with Sunitinib (30, 60, 120mg/kg) failed to inhibit the growth of 4T1 tumors after mouse lung implantation, but significantly inhibited the growth of RENCA tumors[6]. Sunitinib (1mg/kg) treatment of diabetic rats for 4 weeks significantly reduced ovarian stromal degeneration, stromal fibrosis, follicular degeneration, and immune expression of NF-kappaB[7].

References:
[1] Sun L, Liang C, Shirazian S, et al. Discovery of 5-[5-fluoro-2-oxo-1, 2-dihydroindol-(3 Z)-ylidenemethyl]-2, 4-dimethyl-1 H-pyrrole-3-carboxylic acid (2-diethylaminoethyl) amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase[J]. Journal of medicinal chemistry, 2003, 46(7): 1116-1119.
[2] Ali M M U, Bagratuni T, Davenport E L, et al. Structure of the Ire1 autophosphorylation complex and implications for the unfolded protein response[J]. The EMBO journal, 2011, 30(5): 894-905.
[3] Gridelli C, Maione P, Del Gaizo F, et al. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer[J]. The oncologist, 2007, 12(2): 191-200.
[4] Van Der Mijn J C, Broxterman H J, Knol J C, et al. Sunitinib activates Axl signaling in renal cell cancer[J]. International journal of cancer, 2016, 138(12): 3002-3010.
[5] Yang F, Jove V, Xin H, et al. Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways[J]. Molecular Cancer Research, 2010, 8(1): 35-45.
[6] Welti J C, Powles T, Foo S, et al. Contrasting effects of sunitinib within in vivo models of metastasis[J]. Angiogenesis, 2012, 15: 623-641.
[7] Erbas O, Pala H G, Pala E E, et al. Therapeutic effect of sunitinib on diabetes mellitus related ovarian injury: an experimental rat model study[J]. Gynecological Endocrinology, 2015, 31(5): 388-391.

舒尼替尼Sunitinib(SU 11248)是一种具口服活性的多靶点受体酪氨酸激酶抑制剂,对血管内皮生长因子受体(VEGFR2)和血小板衍生生长因子受体(PDGFRβ)的IC50分别为80nM和2nM[1]。Sunitinib是一种ATP竞争性抑制剂,通过抑制自身磷酸化和随后的RNase激活,有效抑制Ire1α的磷酸化[2]。Sunitinib通常用于治疗晚期肾细胞癌和胃肠道间质癌,以及非小细胞肺癌等[3]

在体外,Sunitinib(2、5μM)处理肾癌细胞786-O,诱导了胞内磷酸化蛋白质组变化,180 种磷酸肽显示出>1.5倍的变化,86个磷酸肽下调,94个磷酸肽上调[4]。Sunitinib(0-5μM)处理髓母细胞瘤 VC312 细胞24h或48h,以剂量依赖性方式增加了裂解的caspase-3和PARP水平,诱导了细胞凋亡,抑制了STAT3和AKT活性[5]

在体内,Sunitinib(30、60、120mg/kg)通过口服治疗接种4T1-luc和RENCA-luc肿瘤细胞的小鼠,无法抑制4T1肿瘤在小鼠肺部植入后的生长,但可以显著抑制RENCA肿瘤的生长[6]。Sunitinib(1mg/kg)治疗糖尿病大鼠4周,显著降低了卵巢的间质变性、间质纤维化、卵泡变性以及NF-kappaB的免疫表达[7]

Chemical Properties

Cas No. 557795-19-4 SDF
别名 舒尼替尼; SU 11248
化学名 N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
Canonical SMILES CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C
分子式 C22H27FN4O2 分子量 398.47
溶解度 ≥ 19.9mg/mL in DMSO with gentle warming 储存条件 Store at -20°C
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 2.5096 mL 12.548 mL 25.096 mL
5 mM 0.5019 mL 2.5096 mL 5.0192 mL
10 mM 0.251 mL 1.2548 mL 2.5096 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置